

Mumbai, February 4, 2015

**Wockhardt Q3FY15 Net Sales at Rs.1382 crore and  
PAT at 347 crore**

	Q3-FY15		Q3-FY14	9MFY15		FY14
	Oct - Dec 2014		Oct - Dec 2013	Apr - Dec 2014		
	Rsc	Gwth Y-O-Y	Rsc	Rsc	Gwth Y-O-Y	
<b>Sales</b>	<b>1,382</b>	<b>12%</b>	<b>1,237</b>	<b>3,402</b>	<b>-10%</b>	<b>4,830</b>
<b>R&amp;D</b>	<b>119</b>	<b>21%</b>	<b>98</b>	<b>340</b>	<b>13%</b>	<b>403</b>
<b>R&amp;D % to Sales</b>	<b>8.6%</b>		<b>7.9%</b>	<b>10.0%</b>		<b>8.3%</b>
<b>Operating Profit</b>	<b>463</b>	<b>92%</b>	<b>241</b>	<b>689</b>	<b>-20%</b>	<b>980</b>
<b>Op. Profit Margins %</b>	<b>33.5%</b>		<b>19.5%</b>	<b>20.3%</b>		<b>20.3%</b>
<b>Profit After Tax</b>	<b>347</b>	<b>14%</b>	<b>304</b>	<b>371</b>	<b>-52%</b>	<b>841</b>
<b>PAT Margins</b>	<b>25.1%</b>		<b>24.6%</b>	<b>10.9%</b>		<b>17.4%</b>
<b>EPS</b>	<b>31.6</b>		<b>27.7</b>	<b>33.7</b>	<b>-52%</b>	<b>76.6</b>

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 3<sup>rd</sup> quarter and Nine month results for Financial Year 2015, today.

**Quarter ended 31<sup>st</sup> December, 2014**

Consolidated revenue for the quarter grown by 12% at Rs.1382 crore and EBIDTA by 92% at Rs. 463 crore.

Profit After Tax for the quarter was Rs.347 crore with PAT margin at about 25.1%.

The company increased its Research spend significantly and the same is now at 8.6% to sales at Rs.119 crores and including capital expenditure is at 8.9% to sales for the quarter.

**PRESS RELEASE**

**WOCKHARDT**

Wockhardt filed for 42 patents during the quarter taking the cumulative filings to 2107 and has been granted 21 patents during the quarter taking the cumulative patents granted to 321.

### **Nine Months ended 31<sup>st</sup> December, 2014**

Consolidated revenue for the Nine Month was Rs.3402 crore and Profit After Tax was at Rs.371 crore.

Research expenses stood at Rs.340 crores for the Nine Month representing 10% of sales and including capital expenditure is at 10.6% of sales.

UK made 8 new filings during the Nine Month.

### **Capex**

Capital expenditure of Rs.289 crore was incurred in Nine Month of FY15.

### **Business Highlights**

The India business recorded a growth of 15% in Q3FY15 and grew by 17% in Nine Months of FY15. Emerging Markets business grew by 28% in Q3FY15 and by 15% in Nine Months of FY15.

Wockhardt's International Business contributed 79% of the Total Revenues during the quarter.

The UK business recorded a growth of 141% in Q3FY15 (in £ terms 130%) and growth of 49% in 9MFY15 (in £ terms 36%). The Irish market declined by 37% in Q3FY15 (in € terms 36%) and 10% in 9MFY15 (in € terms 13%).

Wockhardt's US business declined by 48% in Q3FY15 and declined by 55% in Nine Months of FY15 and contributed 20% of the Global Revenues for Wockhardt in Q3FY15 and 24% in Nine Months of FY15.

Wockhardt launched 7 new products in Domestic Market in Q3FY15 and 40 new products in 9MFY15.

**PRESS RELEASE**



**Wockhardt Limited**

| Wockhardt Towers |  
| Bandra Kurla Complex |  
| Mumbai 400 051 | India |  
| Tel.: +91-22-2653 4444 |  
| [www.wockhardt.com](http://www.wockhardt.com)

---

**About Wockhardt :**

Wockhardt is a highly technology intensive global pharmaceutical and biotechnology company. It's multi-disciplinary and innovative R&D programmes globally, are strongly focused on creating Intellectual Properties. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 79% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 850 scientists, of whom 80 are doctorates. In all, Wockhardt has 321 Patents granted worldwide. In biotechnology research, it has built competent 'Concept to Market' capability in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 8,600 people from 21 different nationalities.